Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Return on Assets (2016 - 2025)

Avalo Therapeutics' Return on Assets history spans 11 years, with the latest figure at 0.65% for Q4 2025.

  • For Q4 2025, Return on Assets fell 37.0% year-over-year to 0.65%; the TTM value through Dec 2025 reached 0.65%, down 37.0%, while the annual FY2025 figure was 0.59%, 18.0% down from the prior year.
  • Return on Assets reached 0.65% in Q4 2025 per AVTX's latest filing, up from 0.79% in the prior quarter.
  • In the past five years, Return on Assets ranged from a high of 0.5% in Q1 2025 to a low of 1.97% in Q1 2024.
  • Average Return on Assets over 5 years is 0.37%, with a median of 0.28% recorded in 2024.
  • Peak YoY movement for Return on Assets: crashed -169bps in 2024, then soared 248bps in 2025.
  • A 5-year view of Return on Assets shows it stood at 0.0% in 2021, then tumbled by -538bps to 0.0% in 2022, then crashed by -66299bps to 1.26% in 2023, then skyrocketed by 78bps to 0.28% in 2024, then crashed by -130bps to 0.65% in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Return on Assets are 0.65% (Q4 2025), 0.79% (Q3 2025), and 0.35% (Q2 2025).